Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas

Jeremiah Deneve, Jonathan S. Zager

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Patients presenting with unresectable, large, primary or recurrent extremity soft tissue sarcoma or locally advanced extremity tumors may benefit from treatment options in the form of isolated regional perfusion therapy. Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) have proved to be efficacious with acceptable systemic and regional toxicity profiles. Both procedures are attractive as options for patients who might otherwise be facing amputation as limb salvage procedures. HILP and ILI can be offered as either definitive treatment or as neoadjuvant therapy followed by surgery and/or radiation treatment. Response rates are encouraging as are limb preservation rates after regional therapy. Ongoing multicenter collaborations and clinical trials are required to gain knowledge on HILP and ILI for unresectable extremity sarcoma and expand the indications for use in the management of advanced extremity soft tissue sarcoma.

Original languageEnglish (US)
Pages (from-to)287-299
Number of pages13
JournalSurgical Oncology Clinics of North America
Volume21
Issue number2
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Sarcoma
Extremities
Perfusion
Therapeutics
Limb Salvage
Neoadjuvant Therapy
Amputation
Multicenter Studies
Clinical Trials
Radiation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Surgery

Cite this

Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas. / Deneve, Jeremiah; Zager, Jonathan S.

In: Surgical Oncology Clinics of North America, Vol. 21, No. 2, 01.04.2012, p. 287-299.

Research output: Contribution to journalReview article

@article{6cf342aaf66c499bbb980243244b2a86,
title = "Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas",
abstract = "Patients presenting with unresectable, large, primary or recurrent extremity soft tissue sarcoma or locally advanced extremity tumors may benefit from treatment options in the form of isolated regional perfusion therapy. Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) have proved to be efficacious with acceptable systemic and regional toxicity profiles. Both procedures are attractive as options for patients who might otherwise be facing amputation as limb salvage procedures. HILP and ILI can be offered as either definitive treatment or as neoadjuvant therapy followed by surgery and/or radiation treatment. Response rates are encouraging as are limb preservation rates after regional therapy. Ongoing multicenter collaborations and clinical trials are required to gain knowledge on HILP and ILI for unresectable extremity sarcoma and expand the indications for use in the management of advanced extremity soft tissue sarcoma.",
author = "Jeremiah Deneve and Zager, {Jonathan S.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.soc.2011.11.003",
language = "English (US)",
volume = "21",
pages = "287--299",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas

AU - Deneve, Jeremiah

AU - Zager, Jonathan S.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Patients presenting with unresectable, large, primary or recurrent extremity soft tissue sarcoma or locally advanced extremity tumors may benefit from treatment options in the form of isolated regional perfusion therapy. Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) have proved to be efficacious with acceptable systemic and regional toxicity profiles. Both procedures are attractive as options for patients who might otherwise be facing amputation as limb salvage procedures. HILP and ILI can be offered as either definitive treatment or as neoadjuvant therapy followed by surgery and/or radiation treatment. Response rates are encouraging as are limb preservation rates after regional therapy. Ongoing multicenter collaborations and clinical trials are required to gain knowledge on HILP and ILI for unresectable extremity sarcoma and expand the indications for use in the management of advanced extremity soft tissue sarcoma.

AB - Patients presenting with unresectable, large, primary or recurrent extremity soft tissue sarcoma or locally advanced extremity tumors may benefit from treatment options in the form of isolated regional perfusion therapy. Hyperthermic isolated limb perfusion (HILP) and isolated limb infusion (ILI) have proved to be efficacious with acceptable systemic and regional toxicity profiles. Both procedures are attractive as options for patients who might otherwise be facing amputation as limb salvage procedures. HILP and ILI can be offered as either definitive treatment or as neoadjuvant therapy followed by surgery and/or radiation treatment. Response rates are encouraging as are limb preservation rates after regional therapy. Ongoing multicenter collaborations and clinical trials are required to gain knowledge on HILP and ILI for unresectable extremity sarcoma and expand the indications for use in the management of advanced extremity soft tissue sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=84857417074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857417074&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2011.11.003

DO - 10.1016/j.soc.2011.11.003

M3 - Review article

VL - 21

SP - 287

EP - 299

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -